A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule Formulation

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions

Healthy Volunteer

Interventions

DRUG

cobimetinib

Single, oral dose given as a tablet on Day 1 after a minimum 8 h fast

DRUG

cobimetinib

Single, oral dose given as 4 capsules on Day 1 after a minimum 8 h fast

Trial Locations (1)

Dallas